The Trojan Horse Hypothesis: Neutrophil Elastase Reprograms Macrophage Function

Information

  • Research Project
  • 10191015
  • ApplicationId
    10191015
  • Core Project Number
    R01HL146811
  • Full Project Number
    5R01HL146811-02
  • Serial Number
    146811
  • FOA Number
    PA-19-056
  • Sub Project Id
  • Project Start Date
    9/1/2020 - 5 years ago
  • Project End Date
    8/31/2024 - a year ago
  • Program Officer Name
    LACHOWICZ-SCROGGINS, MARRAH ELIZABETH
  • Budget Start Date
    9/1/2021 - 4 years ago
  • Budget End Date
    8/31/2022 - 3 years ago
  • Fiscal Year
    2021
  • Support Year
    02
  • Suffix
  • Award Notice Date
    8/25/2021 - 4 years ago

The Trojan Horse Hypothesis: Neutrophil Elastase Reprograms Macrophage Function

PROJECT SUMMARY In Cystic Fibrosis (CF), airway innate immunity is breached. Macrophage phagocytosis and efferocytosis fail, and macrophages augment airway inflammation by production of excess cytokines and release of High Mobility Group Box 1 (HMGB1), a damage associated molecular pattern. Although loss of CFTR impacts macrophage function, the CF airway milieu, which is typified by micromolar concentrations of neutrophil elastase (NE), is an overwhelming stimulus, activating a robust pro-inflammatory response in macrophages from both CF and healthy subjects. We propose that NE, a biomarker for lung disease progression in CF subverts macrophage function from protective to pro- inflammatory, yet the mechanisms by which NE reprograms the macrophage are not completely understood. In this application, we present an unprecedented hypothetical mechanism to explain how NE alters macrophage function. Extracellular NE is rapidly endocytosed by the macrophage. But instead of being degraded, proteolytically active NE is localized to both cytoplasmic domains and the nucleus, resulting in increased cytokine expression and release of macrophage extracellular traps (METs). Thus, NE functions like a Trojan Horse to subvert macrophage function. We will test this hypothesis in primary human blood monocyte derived macrophages from healthy volunteers and subjects with CF. The Specific Aims follow: Aim 1. To determine whether NE degrades HDACs, resulting in acetylation of downstream targets, leading to transcriptional upregulation of TNF? and release of HMGB1. Aim 2. To evaluate whether NE protease activity and/or NE-generated reactive oxygen species increase release of mitochondrial and nuclear METs. RELEVANCE: Results from this project will define a novel mechanism utilized by NE to promote sustained airway inflammation, the major cause of morbidity and mortality in CF, and identify targets for new therapies to interrupt the relentless progression of lung disease.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R01
  • Administering IC
    HL
  • Application Type
    5
  • Direct Cost Amount
    374963
  • Indirect Cost Amount
    207167
  • Total Cost
    582130
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    837
  • Ed Inst. Type
    SCHOOLS OF MEDICINE
  • Funding ICs
    NHLBI:582130\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    LCMI
  • Study Section Name
    Lung Cellular, Molecular, and Immunobiology Study Section
  • Organization Name
    VIRGINIA COMMONWEALTH UNIVERSITY
  • Organization Department
    PEDIATRICS
  • Organization DUNS
    105300446
  • Organization City
    RICHMOND
  • Organization State
    VA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    232980568
  • Organization District
    UNITED STATES